Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HANK 2nd Generation NK Cell Enhancer
- Development stage
- Preclinical
- Lead developer
- Shenzhen HANK Bioengineering
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies, Cytokines & Interferons → Recombinant Proteins and Enzymes
01
Overview
HANK 2nd Generation NK Cell Enhancer is a cell therapy enhancement technology developed by Shenzhen HANK Bioengineering. It utilizes a lipid membrane-based platform to embed specific cytokines, designed to augment the function, proliferation, and persistence of Natural Killer (NK) cells. By embedding cytokines directly into a lipid membrane, the technology aims to provide sustained and localized signaling to NK cells, improving their therapeutic efficacy in anti-tumor and antiviral applications. This second-generation product is part of a broader platform focused on optimizing cell therapy outcomes through advanced culture and activation techniques.
- Other names
- HANK细胞第二代NK细胞增效剂HANK 2nd Generation NK Cell EnhancerHANK2nd Generation NK Cell EnhancerHANK-2nd Generation NK Cell Enhancer
Beyond the preview
Go deeper on HANK 2nd Generation NK Cell Enhancer.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HANK 2nd Generation NK Cell Enhancer.